Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.

about

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.

Item

http://www.wikidata.org/entity/Q50193922

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.

@en

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.

@nl

type

Item

label

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.

@en

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.

@nl

prefLabel

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.

@en

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.

@nl

P1476

Inhibited, trapped or adducted: the optimal selective synthetic lethal mix for BRCAness.

@en

P2093

A Tutt

http://www.w3.org/2001/XMLSchema#string

P2860

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Role of poly(ADP-ribose) formation in DNA repair.

The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.

Platinum compounds in the treatment of advanced breast cancer.

Tracing the network connecting BRCA and Fanconi anaemia proteins.

Molecular pathogenesis of Fanconi anemia: recent progress.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

P304

18-21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1093/ANNONC/MDX775

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29300815

http://www.w3.org/2001/XMLSchema#string

P932

5834033

http://www.w3.org/2001/XMLSchema#string